EUROPEAN SYMPOSIUM
Optimal use of clotting factors and immunoglobulins
26-27 April 2013, Wildbad Kreuth, Germany
Duration: 2,5 days. Working language: English
***
PROGRAMME
26-27 April 2013 – Hanns Seidl Stiftung, Wildbad Kreuth, GERMANY
PROGRAMME: OPTIMAL USE OF CF AND IG
THURSDAY 25 APRIL 2013
16:00-18:00
- Poster set-up for manufacturers
- Registration for participants
- Pre-meeting for speakers
19:00-21:30
Buffet Dinner
FRIDAY 26 APRIL 2013
8:00 Welcome
Dr Karl-Heinz Buchheit, EDQM, Council of Europe
SESSION 1: General information on the clinical use
of clotting factors and immunoglobulins
Moderator: Karl-Heinz Buchheit
Rapporteurs: Rainer Seitz & Harvey Klein
8:15-8:30
Key lecture
Optimal clinical use of blood and plasma derivatives
Background and perspectives
Harvey Klein, National Institute of Health, Bethesda, USA
8:30-9:15
Rationale for the meeting
Clinical use of immunoglobulins
Hans-Hartmut Peter, University of Freiburg, DE
Clinical use of clotting factors (plasma-derived and recombinant)
Wolfgang Schramm, University of Munich, DE
Regulations for plasma-derived and recombinant medicinal products
Rainer Seitz, Paul Ehrlich Institut, Langen, DE
9:15-9:30
Clinical challenges and access to clotting factor concentrates in
haemophilia in Europe
Paul Giangrande, Churchill Hospital, Oxford, UK
9:30-9:45
Current data on the use of clotting factors and immunoglobulins in
Europe
Patrick Robert, The Marketing Research Bureau, Inc, Orange, USA
9:45-10:00
Report on the outcome of the EDQM surveys
Karin Berger, University Hospital of Munich, DE
Jacqueline Kerr, Paul-Ehrlich-Institut, Langen, DE
10:00-10:30
Coffee break and poster viewing
J
SESSION 2: Clotting Factors
26-27 April 2013 – Hanns Seidl Stiftung, Wildbad Kreuth, GERMANY
PROGRAMME: OPTIMAL USE OF CF AND IG
Moderators & Rapporteurs: Wolfgang Schramm & Rainer Seitz
10:30-10:45
Patients organisations’ view - Access and unmet needs
Brian O’Mahony, European Haemophilia Consortium (EHC), City, Country
10:45-11:05
New developments in clinical research and new treatment modalities
– A clinician’s perspective
Pier Mannucci, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation,
Milan, IT
11:05-11:25
Benefits and limitations with innovative clotting factor preparations
Flora Peyvandi, University of Milan, IT
11:25-11:45
European clinical guidelines
Cedric Hermans, Cliniques Universitaires Saint Luc, BE
11:45-12:00
European regulatory perspective
Anneliese Hilger, Paul Ehrlich Institut, Langen, DE
12:00-12:15
Registries
Mike Makris, Royal Hallamshire Hospital, Sheffield, UK
12:15-13:30
Lunch break and poster viewing
SESSION 3: Immunoglobulins
Moderators & Rapporteurs: Hans-Hartmut Peter, Isabella Quinti & Carrock Sewell
13:30-13:45
Patients Organisations’ view - Access and unmet needs
Jose Drabwell, International Patient Organisation for Primary
Immunodeficiencies
13:45-14:05
Clinically established indications in primary
immunodeficiencies
Helen Chapel, John Radcliffe Hospital, Oxford, UK
presented by Hans-Harmut Peter
14:05-14:25
Immunomodulation: On-label and off-label Usage
Ivo Van Schaik, University of Amsterdam, NL
14:25-14:40
European regulatory perspective
Jacqueline Kerr, Paul Ehrlich Institut, Langen, DE
14:40-14:55
Demand Management Plan
Carrock Sewell, Scunthorpe General Hospital, UK
14:55-15:10
Innovative products and new developments - cancelled
Lennart Hammarström, Karolinska Institute, Stockholm, SE
15:10-15:25
Registries
Bodo Grimbacher, University of Freiburg, DE
15:25-16:00
Coffee break and poster viewing
and
secondary
SESSION 4: Working Groups Session
26-27 April 2013 – Hanns Seidl Stiftung, Wildbad Kreuth, GERMANY
PROGRAMME: OPTIMAL USE OF CF AND IG
16:00-18:00 Working Group 1: Clotting factors
Moderators: Pier Mannucci, Wolfgang Schramm
Rapporteurs: Pier Mannuci, Paul Giangrande, Wolfgang Schramm
16:00-18:00 Working Group 2: Immunoglobulins
Moderators: Hans-Hartmut Peter, Jacqueline Kerr
Rapporteurs: Hans-Hartmut Peter, Jacqueline Kerr, Isabella Quinti &
Carrock Sewell
18:00
Close of meeting
20:00
Evening Dinner
SATURDAY 27 APRIL 2013 – CLOSED MEETING
8:00-9:00
Interim reports from Working Groups
9:00-10:45
Discussion in the Working Groups
10:45-11:00
Coffee break
11:00-12:30
Final reports from the Working Groups
Moderators: Rainer Seitz & Karl-Heinz Buchheit


Working Group 1: Clotting factor
Working Group 2: Immunoglobulins
12:30-13:30
Lunch break
13:30-16:00
Conclusions and Recommendations
SCIENTIFIC PROGRAMME COMMITTEE
Prof Dr Rainer SEITZ
Dr Marie-Emmanuelle BEHR-GROSS
Dr Karl-Heinz BUCHHEIT
Prof Dr Wolfgang SCHRAMM
Ms Karin BERGER
Dr Anneliese HILGER
Dr Jacqueline KERR
Prof Dr Hans-Hartmut PETER
Meeting Venue:see http://www.hss.de/fileadmin/media/downloads/Anfahrtsskizze_WildbadKreuth.pdf http://www.hss.de/bildungszentren/wildbad-kreuth.html